TY - JOUR
T1 - Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype
AU - Rossetti, Sandro
AU - Chauveau, Dominique
AU - Kubly, Vickie
AU - Slezak, Jeffrey M.
AU - Saggar-Malik, Anand K.
AU - Pei, York
AU - Ong, Albert C.M.
AU - Stewart, Fiona
AU - Watson, Michael L.
AU - Bergstralh, Erik J.
AU - Winearls, Christopher G.
AU - Torres, Vicente E.
AU - Harris, Peter C.
N1 - Funding Information:
We thank D Walker for technical assistance, S Burton for collection of patients' data, J-P Grünfeld for support and guidance, and the patients and their families for taking part in the study. This work was supported by National Institutes of Health grant DK58816, a PKD Foundation fellowship to SR, a SNAM-HP grant to DC, the Mayo Foundation, the Canadian Institute for Health Research, and the National Kidney Research Fund (UK).
PY - 2003/6/28
Y1 - 2003/6/28
N2 - Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at risk of developing intracranial aneurysms, and subarachnoid haemorrhage is a major cause of death and disability. Familial clustering of intracranial aneurysms suggests that genetic factors are important in the aetiology. We tested whether the germline mutation predisposes to this vascular phenotype. Methods: DNA samples from patients with ADPKD and vascular complications were screened for mutations throughout the PKD1 and PKD2 genes. Comparisons were made between the PKD1 and PKD2 populations and with a control PKD1 cohort (without the vascular phenotype). Findings: Mutations were characterised in 58 ADPKD families with vascular complications; 51 were PKD1 (88%) and seven PKD2 (12%). The median position of the PKD1 mutation was significantly further 59 in the vascular population than in the 87 control pedigrees (aminoacid position 2163 vs 2773, p=0.0034). Subsets of the vascular population with aneurysmal rupture, early rupture, or families with more than one vascular case had median mutation locations further 59 (aminoacid position 1811, p=0.0018; 1671, p=0.0052; and 1587, p=0.0003). Interpretation: Patients with PKD2, as well as those with PKD1, are at risk of intracranial aneurysm. The position of the mutation in PKD1 is predictive for development of intracranial aneurysms (59 mutations are more commonly associated with vascular disease) and is therefore of prognostic importance. Since the PKD1 phenotype is associated with mutation position, the disease is not simply due to loss of all disease allele products.
AB - Background: Patients with autosomal dominant polycystic kidney disease (ADPKD) are at risk of developing intracranial aneurysms, and subarachnoid haemorrhage is a major cause of death and disability. Familial clustering of intracranial aneurysms suggests that genetic factors are important in the aetiology. We tested whether the germline mutation predisposes to this vascular phenotype. Methods: DNA samples from patients with ADPKD and vascular complications were screened for mutations throughout the PKD1 and PKD2 genes. Comparisons were made between the PKD1 and PKD2 populations and with a control PKD1 cohort (without the vascular phenotype). Findings: Mutations were characterised in 58 ADPKD families with vascular complications; 51 were PKD1 (88%) and seven PKD2 (12%). The median position of the PKD1 mutation was significantly further 59 in the vascular population than in the 87 control pedigrees (aminoacid position 2163 vs 2773, p=0.0034). Subsets of the vascular population with aneurysmal rupture, early rupture, or families with more than one vascular case had median mutation locations further 59 (aminoacid position 1811, p=0.0018; 1671, p=0.0052; and 1587, p=0.0003). Interpretation: Patients with PKD2, as well as those with PKD1, are at risk of intracranial aneurysm. The position of the mutation in PKD1 is predictive for development of intracranial aneurysms (59 mutations are more commonly associated with vascular disease) and is therefore of prognostic importance. Since the PKD1 phenotype is associated with mutation position, the disease is not simply due to loss of all disease allele products.
UR - http://www.scopus.com/inward/record.url?scp=0037830054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037830054&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(03)13773-7
DO - 10.1016/S0140-6736(03)13773-7
M3 - Article
C2 - 12842373
AN - SCOPUS:0037830054
SN - 0140-6736
VL - 361
SP - 2196
EP - 2201
JO - The Lancet
JF - The Lancet
IS - 9376
ER -